医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReForm Biologics Announces Collaboration Agreement with Astellas Pharma Inc.

2019年03月05日 PM09:00
このエントリーをはてなブックマークに追加


 

WOBURN, Mass.

ReForm Biologics, a privately-held pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503,”Astellas”) to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform transforms the formulation of biotherapeutics in order to enable alternative dosing, improve manufacturing efficiency and extend product life-cycles.

Under the terms of the agreement, Astellas will provide funding for the collaboration and the work will be performed at ReForm Biologics’ facilities in Woburn, Massachusetts.

“We are excited to initiate this collaboration with Astellas, a global leader in turning innovative science into value for patients. We appreciate the efforts of Astellas Innovation Management team in getting the agreement completed,” said John M. Sorvillo, Ph.D., Chief Executive Officer, ReForm Biologics. “This collaboration will demonstrate how new formulation technologies can optimize dosing and support life cycle management in pharmaceutical drug development programs. We look forward to working with Astellas to support the development of this clinical-stage asset.”

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented, FDA-friendly technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

About Astellas Pharma Inc.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at http://www.astellas.com/en

View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005246/en/

CONTACT

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Genetron Health Announces Strategic Collaboration with CStone
  • PCIファーマ・サービシズが英国トレデガー施設の開発・製造能力を拡大するための大規模投資を発表
  • 21St Century Oncology to Join Australia’s GenesisCare in a Partnership to Increase Access to High Quality Cancer Care in U.S. Communities
  • Konkuk University Research Team Identifies Drought-tolerant Process of Plants at the Molecular Level
  • Dabur Research Foundation™ and Flowerkist Incorporated™ to Co-Develop and Launch a Wide Range of CBD Infused Topical Therapeutic and Age Management Products